Table 3.
Intraocular Pressure Across Treatment Groups and Time Points
| |
Baseline |
2 weeks |
3 months |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8:00 AM | 10:00 AM | 3:00 PM | 5:00 PM | 8:00 AM | 10:00 AM | 3:00 PM | 5:00 PM | 8:00 AM | 10:00 AM | 3:00 PM | 5:00 PM | |
| BBFC, n | 218 | 218 | 218 | 218 | 218 | 214 | 212 | 211 | 196 | 194 | 194 | 194 |
| Mean±SD | 27.2±2.8 | 25.8±3.1 | 24.4±3.7 | 24.1±3.7 | 20.0±3.8 | 16.9±3.5 | 18.3±3.9 | 16.0±3.5 | 20.5±3.9 | 17.5±3.8 | 19.0±3.8 | 16.7±3.9 |
| LS mean±SE | NA | NA | NA | NA | 20.5±0.3 | 17.4±0.3 | 18.7±0.3 | 16.5±0.3 | 21.1±0.3 | 18.0±0.3 | 19.5±0.3 | 17.2±0.3 |
| Brinzolamide, n | 229 | 229 | 229 | 229 | 229 | 227 | 227 | 227 | 216 | 213 | 212 | 212 |
| Mean±SD | 27.2±2.7 | 26.0±3.2 | 24.4±3.6 | 24.2±3.9 | 21.7±4.4 | 20.3±3.6 | 20.1±3.7 | 19.7±3.6 | 21.4±4.2 | 20.2±3.8 | 20.1±4.0 | 19.8±3.9 |
| LS mean±SE | NA | NA | NA | NA | 22.2±0.3 | 20.7±0.3 | 20.5±0.3 | 20.1±0.3 | 22.0±0.3 | 20.8±0.3 | 20.7±0.3 | 20.4±0.3 |
| Brimonidine, n | 232 | 232 | 232 | 232 | 230 | 226 | 226 | 222 | 203 | 201 | 200 | 199 |
| Mean±SD | 27.3±2.7 | 25.8±3.0 | 24.0±3.4 | 23.7±3.6 | 22.5±4.0 | 18.8±3.8 | 20.6±4.0 | 17.8±3.8 | 22.5±4.1 | 19.0±3.7 | 20.7±4.2 | 18.0±4.2 |
| LS mean±SE | NA | NA | NA | NA | 22.8±0.3 | 19.2±0.3 | 21.1±0.3 | 18.3±0.3 | 23.2±0.3 | 19.9±0.3 | 21.5±0.3 | 18.9±0.3 |
| P-valuea | ||||||||||||
| BBFC vs. brinz | NA | NA | NA | NA | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.005 | <0.0001 | 0.0008 | <0.0001 |
| BBFC vs. brim | NA | NA | NA | NA | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Intraocular pressure was analyzed using the intent-to-treat population.
a
Pairwise t-test based on LS means.
SD, standard deviation; LS, least squares; SE, standard error; NA, not applicable.